Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC Breakpoint
George L. Drusano(University of Florida), William A. Craig(William S. Middleton Memorial Veterans Hospital), David R. Andes(University of Wisconsin–Madison), C. Hardalo, Christopher Banfield, Sandra L. Preston(Albany Medical Center Hospital), R S Hare, Ómar Vesga(University of Wisconsin–Madison)
Cited by 242
Related Papers
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2015|4k
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.2k
State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men
|Clinical Infectious Diseases|1998|2.9k